News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
210,498 Results
Type
Article (22208)
Company Profile (25)
Press Release (188263)
Multimedia
Podcasts (63)
Webinars (5)
Section
Business (54335)
Career Advice (875)
Deals (8369)
Drug Delivery (70)
Drug Development (35975)
Employer Resources (64)
FDA (6517)
Job Trends (5124)
News (101758)
Policy (14959)
Tag
2027 Bio NC Standard (1)
2027 Genetown Standard (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (2)
Academia (1284)
Accelerated approval (28)
ADA (9)
Adcomms (23)
Allergies (124)
Alliances (14072)
ALS (74)
Alzheimer's disease (1124)
Antibody-drug conjugate (ADC) (198)
Approvals (6779)
Artificial intelligence (223)
ASCO (107)
Autoimmune disease (118)
Automation (14)
Bankruptcy (90)
Best Places to Work (4449)
BIO (16)
BIOSECURE Act (8)
Biosimilars (138)
BioSpace Insights (32)
Biotechnology (22)
Bladder cancer (98)
Brain cancer (38)
Breast cancer (270)
Cancer (2283)
Cardiovascular disease (223)
Career advice (738)
Career pathing (24)
CAR-T (131)
CDC (48)
Cell therapy (359)
Cervical cancer (21)
Clinical research (30360)
Collaboration (719)
Company closure (2)
Compensation (184)
Complete response letters (40)
COVID-19 (2318)
CRISPR (45)
C-suite (346)
Cystic fibrosis (65)
Data (3734)
Decentralized trials (2)
Denatured (4)
Depression (60)
Dermatology (55)
Diabetes (274)
Diagnostics (1863)
Digital health (17)
Diversity (7)
Diversity, equity & inclusion (26)
Drug discovery (143)
Drug pricing (125)
Drug shortages (17)
Duchenne muscular dystrophy (216)
Earnings (19743)
Editorial (46)
Employer branding (11)
Employer resources (66)
Events (25362)
Executive appointments (310)
FDA (8283)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (15)
Frontotemporal dementia (19)
Funding (637)
Gene editing (88)
Generative AI (25)
Gene therapy (394)
GLP-1 (497)
Government (2671)
Grass and pollen (5)
Guidances (183)
Healthcare (6143)
Hematology (78)
HIV (53)
Huntington's disease (33)
IgA nephropathy (64)
Immunology and inflammation (149)
Immuno-oncology (41)
Indications (108)
Infectious disease (2619)
Inflammatory bowel disease (62)
Inflation Reduction Act (8)
Influenza (118)
Intellectual property (82)
Interviews (168)
IPO (3753)
IRA (35)
Job creations (846)
Job search strategy (616)
JPM (35)
Kidney cancer (10)
Labor market (39)
Layoffs (211)
Leadership (21)
Legal (5238)
Licensing (3)
Liver cancer (36)
Longevity (33)
Lung cancer (295)
Lymphoma (182)
Machine learning (15)
Management (20)
Manufacturing (322)
Marketing (7)
MASH (41)
Medical device (2799)
Medtech (2839)
Mergers & acquisitions (5013)
Metabolic disorders (665)
mRNA (162)
Multiple sclerosis (105)
NASH (4)
Neurodegenerative disease (218)
Neuropsychiatric disorders (44)
Neuroscience (1790)
Neurotech (1)
NextGen: Class of 2026 (2065)
Non-profit (1847)
Now hiring (10)
Obesity (318)
Opinion (182)
Ovarian cancer (75)
Pain (71)
Pancreatic cancer (118)
Parkinson's disease (165)
Partnered (10)
Patents (205)
Patient recruitment (281)
Peanut (52)
People (13925)
Pharmaceutical (6)
Pharmacy benefit managers (11)
Phase 1 (9025)
Phase 2 (12948)
Phase 3 (11094)
Pipeline (4216)
Policy (185)
Postmarket research (1285)
Preclinical (4010)
Press Release (14)
Prostate cancer (108)
Psychedelics (38)
Radiopharmaceuticals (131)
Rare diseases (646)
Real estate (1014)
Recruiting (26)
Regulatory (9917)
Reports (23)
Research institute (1088)
Resumes & cover letters (148)
Rett syndrome (35)
RNA editing (6)
RSV (91)
Schizophrenia (61)
Series A (93)
Series B (71)
Service/supplier (1)
Sickle cell disease (62)
Special edition (13)
Spinal muscular atrophy (134)
Sponsored (18)
Startups (1081)
Stomach cancer (10)
Supply chain (45)
Tariffs (56)
The Weekly (59)
Vaccines (1056)
Venture capital (61)
Weight loss (234)
Women's health (51)
Worklife (9)
Date
Today (7)
Last 7 days (242)
Last 30 days (684)
Last 365 days (9464)
2026 (5744)
2025 (9902)
2024 (11432)
2023 (12786)
2022 (18645)
2021 (20121)
2020 (18035)
2019 (14315)
2018 (10813)
2017 (9907)
2016 (9503)
2015 (10716)
2014 (7556)
2013 (5939)
2012 (6042)
2011 (6460)
2010 (5839)
Location
Africa (356)
Alabama (18)
Alaska (1)
Arizona (77)
Arkansas (2)
Asia (12956)
Australia (2568)
California (4094)
Canada (1085)
China (516)
Colorado (147)
Connecticut (186)
Delaware (149)
Europe (37415)
Florida (683)
Georgia (153)
Hawaii (3)
Idaho (11)
Illinois (338)
India (41)
Indiana (312)
Iowa (3)
Japan (270)
Kansas (55)
Kentucky (18)
Louisiana (18)
Maine (30)
Maryland (568)
Massachusetts (3038)
Michigan (80)
Minnesota (138)
Mississippi (1)
Missouri (59)
Montana (8)
Nebraska (5)
Nevada (41)
New Hampshire (24)
New Jersey (1425)
New Mexico (8)
New York (1247)
North Carolina (485)
North Dakota (2)
Northern California (2108)
Ohio (81)
Oklahoma (3)
Oregon (6)
Pennsylvania (941)
Puerto Rico (3)
Rhode Island (12)
South America (382)
South Carolina (16)
South Dakota (1)
Southern California (1559)
Tennessee (56)
Texas (467)
United States (14961)
Utah (100)
Vermont (1)
Virginia (58)
Washington D.C. (28)
Washington State (344)
Wisconsin (27)
210,498 Results for "novartis ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Job Trends
Novartis slashes New Jersey workforce again, cutting 322 employees
With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts have been at the company’s East Hanover, New Jersey, location.
July 7, 2026
·
1 min read
·
Angela Gabriel
Radiopharmaceuticals
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
The discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.
July 22, 2026
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
The FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for their recently approved IgAN therapies Fabhalta and Trutakna.
July 20, 2026
·
2 min read
·
Tristan Manalac
Earnings
Novartis stays ‘geography-agnostic’ in dealmaking amid flurry of China deals
Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma’s second quarter earnings call—though major pickups aren’t completely off the table.
July 21, 2026
·
2 min read
·
Tristan Manalac
Deals
Novartis, Antares stars align in cancer deal that could top $1.9B
Novartis and Antares Therapeutics are shooting for the stars, launching a joint mission to develop small molecule oncology therapies.
June 24, 2026
·
2 min read
·
Gabrielle Masson
Deals
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
It’s the latest Big Pharma deal for molecular glue technology and Novartis’ second with Orionis Biosciences, after first linking up in March 2020. The backloaded agreement will see Novartis pay $40 million upfront.
June 11, 2026
·
2 min read
·
Tristan Manalac
Deals
Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree
The centerpiece of the acquisition is Myricx Bio’s novel N-myristoyltransferase inhibitor payload platform, which could help Novartis develop antibody-drug conjugates that can overcome the limitations of existing therapies.
July 6, 2026
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
June 12, 2026
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
May 26, 2026
·
9 min read
·
Heather McKenzie
Manufacturing
Niowave, fresh from Novartis deal, starts building $75M radioisotope plant
Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.
May 26, 2026
·
2 min read
·
Nick Paul Taylor
1 of 21,050
Next
